Conclusions, take home points, and what to tell my patient...

• Schering-Plough, makers of the first and largest selling IFN alfa-2b preparation (Intron-ATM), has been intimately involved at every point in the evolution of our understanding of treatment of chronic HCV...

• We just don’t know how treatment of chronic hepatitis C impacts progression to cirrhosis and end-stage liver disease, quality of life, and mortality.

Patients must be counseled in light of this.

Previous slide

Next slide

Back to first slide

View graphic version